Viz.ai Raises $100M At $1.2B Valuation To Continue AI-Based Platform Expansion
Israeli medical imaging startup Viz.ai has raised $100 million in a Series D funding round at a $1.2 billion valuation, the company announced on Thursday. Viz.ai is now Israel’s newest unicorn.
The round was led by Tiger Global and Insight Partners. Also joining the round were several of the company‘s early backers, including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.
The new funds will be used to support Viz.ai’s significant growth trajectory, expand the Viz Platform to detect and triage additional diseases, and grow its customer base globally.
The funding comes as the number of hospitals using the Viz platform surpasses the 1,000 mark and patients served reach millions.
“Viz.ai is committed to helping patients get better, faster, and more equitable access to life-saving treatments,” said Chris Mansi, MD, Viz.ai co-founder and CEO. “We will continue to invest heavily in cutting-edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates, and enhance workflows across the entire hub and spoke health system. More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system.”
Founded in 2016, Viz.ai is a medical imaging company that helps optimize emergency treatment using deep learning technology to analyze CT scans and automatically detect and alert physicians of early signs of large vessel occlusion strokes through its Viz LVO platform. The tech introduced the concept of computer-aided triage software, which helps triage patients connect directly to a stroke specialist and fast-track life-saving care.
“The Viz.ai platform has been the single most impactful advance I’ve seen as a physician, permitting the entire care team to mobilize immediately and deliver time-sensitive treatment faster,” said Chris Kellner, MD, a cerebrovascular neurosurgeon in the Mount Sinai Health System in New York. “In addition, Viz Recruit permits us to automatically screen patients for clinical trial enrollment, ensuring we can offer cutting-edge studies and treatments to more eligible patients.”